Randy Davis

1.2k total citations
19 papers, 858 citations indexed

About

Randy Davis is a scholar working on Pathology and Forensic Medicine, Genetics and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Randy Davis has authored 19 papers receiving a total of 858 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pathology and Forensic Medicine, 5 papers in Genetics and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Randy Davis's work include Chronic Lymphocytic Leukemia Research (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Migraine and Headache Studies (3 papers). Randy Davis is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Migraine and Headache Studies (3 papers). Randy Davis collaborates with scholars based in United States, United Kingdom and Czechia. Randy Davis's co-authors include Nedjad Losic, Martin J.S. Dyer, Jiřı́ Mayer, Anders Österborg, Magdalena Piotrowska, Stephan Stilgenbauer, Tadeusz Robak, Marek Trněný, Charlotte Russell and William G. Wierda and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Randy Davis

19 papers receiving 824 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Randy Davis United States 10 448 385 204 196 191 19 858
Masayuki Yamakura Japan 13 298 0.7× 134 0.3× 22 0.1× 161 0.8× 112 0.6× 23 577
Daisuke Hoshi Japan 15 150 0.3× 101 0.3× 112 0.5× 90 0.5× 43 0.2× 53 792
Karin Hellgren Sweden 17 133 0.3× 119 0.3× 307 1.5× 98 0.5× 16 0.1× 48 798
A H M Heurkens Netherlands 7 174 0.4× 206 0.5× 138 0.7× 22 0.1× 38 0.2× 7 1.1k
T. Li United States 6 125 0.3× 173 0.4× 380 1.9× 47 0.2× 15 0.1× 6 1.0k
Michio Sawada Japan 15 302 0.7× 91 0.2× 152 0.7× 81 0.4× 66 0.3× 37 577
Luís Inês Portugal 16 98 0.2× 47 0.1× 458 2.2× 69 0.4× 38 0.2× 62 837
E. Lubberts Netherlands 3 128 0.3× 70 0.2× 127 0.6× 26 0.1× 31 0.2× 4 879
Valeria Maria Pinto Italy 19 102 0.2× 648 1.7× 120 0.6× 80 0.4× 34 0.2× 57 1.0k
Sophie Taque France 14 160 0.4× 86 0.2× 94 0.5× 202 1.0× 37 0.2× 36 929

Countries citing papers authored by Randy Davis

Since Specialization
Citations

This map shows the geographic impact of Randy Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Randy Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Randy Davis more than expected).

Fields of papers citing papers by Randy Davis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Randy Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Randy Davis. The network helps show where Randy Davis may publish in the future.

Co-authorship network of co-authors of Randy Davis

This figure shows the co-authorship network connecting the top 25 collaborators of Randy Davis. A scholar is included among the top collaborators of Randy Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Randy Davis. Randy Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Regnault, Antoine, Boris Gorsh, Randy Davis, et al.. (2023). A toolbox of different approaches to analyze and present PRO-CTCAE data in oncology studies. JNCI Journal of the National Cancer Institute. 115(5). 586–596. 8 indexed citations
2.
Regnault, Antoine, Stéphane Quéré, Boris Gorsh, et al.. (2021). Landscape review of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in oncology: Adoption and recent learnings.. Journal of Clinical Oncology. 39(15_suppl). e18587–e18587. 1 indexed citations
3.
4.
5.
6.
Davis, Randy. (2015). Bridge Programs: A Link between ESL and Content based courses. A Case Study. SHILAP Revista de lepidopterología. 10(1). 181–188. 1 indexed citations
7.
Wierda, William G., Thomas J. Kipps, Jiřı́ Mayer, et al.. (2010). Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 28(10). 1749–1755. 413 indexed citations
8.
Coiffier, Bertrand, André Bosly, Ka Lung Wu, et al.. (2010). Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results From a Multicenter Phase II Study. Blood. 116(21). 3955–3955. 13 indexed citations
9.
Wierda, William G., Thomas J. Kipps, Jiřı́ Mayer, et al.. (2010). Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. Blood. 116(21). 921–921. 16 indexed citations
10.
Wierda, William G., Thomas J. Kipps, Jiřı́ Mayer, et al.. (2009). Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine- and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab. Clinical Lymphoma & Myeloma. 9(6). E36–E36. 3 indexed citations
11.
12.
Funk, Michele L. Jonsson, et al.. (2005). Factors associated with response to lamivudine: Retrospective study in a tertiary care clinic serving patients with chronic hepatitis B. Journal of Gastroenterology and Hepatology. 20(3). 433–440. 7 indexed citations
13.
Keene, Oliver N., Randy Davis, & Gary G. Koch. (2004). Use of generalized estimating equations in a trial in influenza to explore treatment effects over time. Pharmaceutical Statistics. 3(4). 281–287. 4 indexed citations
14.
Davis, Randy & James B. Unger. (2003). Ovarian cancer in women with prior hysterectomy.. PubMed. 155(2). 113–5. 7 indexed citations
15.
Fontana, Robert J., Robert P. Perrillo, John M. Vierling, et al.. (2002). Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology. 123(3). 719–727. 188 indexed citations
16.
Asgharnejad, Mahnaz, et al.. (2001). Efficacy and Tolerability of Subcutaneous Sumatriptan for Acute Migraine: A Comparison Between Ethnic Groups. Headache The Journal of Head and Face Pain. 41(9). 873–882. 13 indexed citations
17.
Cady, Roger, et al.. (1996). Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX® STATdose™ System. Clinical Therapeutics. 18(4). 687–699. 21 indexed citations
18.
Akpunonu, Basil, et al.. (1995). Subcutaneous Sumatriptan for Treatment of Acute Migraine in Patients Admitted to the Emergency Department: A Multicenter Study. Annals of Emergency Medicine. 25(4). 464–469. 89 indexed citations
19.
Davis, Randy & Gary G. Koch. (1994). Statistical considerations for design and analysis of a multiperiod crossover study to compare two treatments for migraine headache. Journal of Biopharmaceutical Statistics. 4(3). 321–346. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masayuki Yamakura Breakdown of academic impact, for papers by Daisuke Hoshi Breakdown of academic impact, for papers by Karin Hellgren Breakdown of academic impact, for papers by A H M Heurkens Breakdown of academic impact, for papers by T. Li Breakdown of academic impact, for papers by Michio Sawada Breakdown of academic impact, for papers by Luís Inês Breakdown of academic impact, for papers by E. Lubberts Breakdown of academic impact, for papers by Valeria Maria Pinto Breakdown of academic impact, for papers by Sophie Taque
Rankless by CCL
2026